Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 5, 2015, Pages 4903-4912

  Chen, Song ^a   Zhang, Xiaojuan ^a   Sun, Yini ^a   Hu, Ziwei ^a   Lu, Siyu ^a   Ma, Xiaochun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Heparanase; Intestinal injury; MAPK; NF B; Sepsis; Unfractionated heparin

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA GLUCURONIDASE; ENZYME INHIBITOR; HEPARANASE; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CECUM; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; INTESTINE; LIGATION; MALE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PUNCTURE; SEPSIS; SIGNAL TRANSDUCTION; SURGERY; TIME FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CECUM; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUCURONIDASE; HEPARIN; INTESTINES; LIGATION; MALE; MICE, INBRED C57BL; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PUNCTURES; SEPSIS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84958582363     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Angus DC, Pereira CA and Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006; 6: 207-212.
2. Clark JA and Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007; 28: 384-393.
3. Kwak YK, Vikstrom E, Magnusson KE, Vecsey-Semjen B, Colque-Navarro P and Mollby R. The Staphylococcus aureus alpha-toxin perturbs the barrier function in Caco-2 epithelial cell monolayers by altering junctional integrity. Infect Immun 2012; 80: 1670-1680.
4. Brell B, Temmesfeld-Wollbruck B, Altzschner I, Frisch E, Schmeck B, Hocke AC, Suttorp N and Hippenstiel S. Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage. Crit Care Med 2005; 33: 819-826.
5. Vlodavsky I, Iozzo RV and Sanderson RD. Heparanase: multiple functions in inflammation, diabetes and atherosclerosis. Matrix Biol 2013; 32: 220-222.
6. Bishop JR, Schuksz M and Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446: 1030-1037.
7. Li JP and Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009; 102: 823-828.
8. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB and Tuder RM. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 2012; 18: 1217-1223.
9. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y, Meirovitz A, Peretz T, Vlodavsky I and Elkin M. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011; 121: 1709-1721.
10. Hermano E, Lerner I and Elkin M. Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell Mol Life Sci 2012; 69: 2501-2513.
11. Casu B and Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001; 57: 159-206.
12. Ning F, Wang X, Shang L, Wang T, Lv C, Qi Z and Wu D. Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats. Gene 2015; 557: 88-91.
13. Li X, Zheng Z and Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-kappaB activation on endothelial cell. Cytokine 2012; 60: 114-121.
14. Wang L, Fuster M, Sriramarao P and Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005; 6: 902-910.
15. Lazebnik LB, Boldyreva ON, Parfenov AI, Trubitsyna IE, Shcherbakov PL, Khomeriki SG, Kniazev OV and Sagynbaeva VE. [Cell adhesion molecules in evaluation of Crohn's disease therapy]. Eksp Klin Gastroenterol 2013; 31-38.
16. Mu E, Ding R, An X, Li X, Chen S and Ma X. Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and transforming growth factor-beta/Smad signaling pathway. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014; 26: 810-814.
17. Ding R, Zhao D, Guo R, Zhang Z and Ma X. Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thromb Res 2011; 128: e160-165.
18. Rittirsch D, Huber-Lang MS, Flierl MA and Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009; 4: 31-36.
19. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
20. Li L, Ling Y, Huang M, Yin T, Gou SM, Zhan NY, Xiong JX, Wu HS, Yang ZY and Wang CY. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine 2015; 72: 36-42.
21. Saliba MJ Jr. Heparin in the treatment of burns: a review. Burns 2001; 27: 349-358.
22. Oremus M, Hanson M, Whitlock R, Young E, Gupta A, Dal Cin A, Archer C and Raina P. The uses of heparin to treat burn injury. Evid Rep Technol Assess (Full Rep) 2006; 1-58.
23. Ghadie MM, Miranda-Ferreira R, Taha NS, Maroso AS, Moreti RJ, Andraus MP, Zempulski P, Monteiro HP, Simoes MJ, Fagundes DJ, Caricati-Neto A and Taha MO. Study of heparin in intestinal ischemia and reperfusion in rats: morphologic and functional evaluation. Transplant Proc 2012; 44: 2300-2303.
24. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM and Elkin M. Versatile role of heparanase in inflammation. Matrix Biol 2013; 32: 234-240.
25. Meirovitz A, Goldberg R, Binder A, Rubinstein AM, Hermano E and Elkin M. Heparanase in inflammation and inflammation-associated cancer. FEBS J 2013; 280: 2307-2319.
26. Lygizos MI, Yang Y, Altmann CJ, Okamura K, Hernando AA, Perez MJ, Smith LP, Koyanagi DE, Gandjeva A, Bhargava R, Tuder RM, Faubel S and Schmidt EP. Heparanase mediates renal dysfunction during early sepsis in mice. Physiol Rep 2013; 1: e00153.
27. Li X, Zheng Z, Liu Y and Ma X. Unfractionated heparin suppresses lipopolysaccharide-in duced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Kruppel-like factor 5 and nuclear factor-kappaB pathway. Immunobio-logy 2014; 219: 778-785.
28. Chen J, Zheng D, Shen J, Ruan J, Li A, Li W, Xie G, Luo X, Zhao P and Zheng H. Heparanase is involved in the proliferation and invasion of nasopharyngeal carcinoma cells. Oncol Rep 2013; 29: 1888-1894.
29. Cui H, Shao C, Liu Q, Yu W, Fang J, Ali A and Ding K. Heparanase enhances nerve-growth-factor-induced PC12 cell neuritogenesis via the p38 MAPK pathway. Biochem J 2011; 440: 273-282.
30. Wu W, Pan C, Meng K, Zhao L, Du L, Liu Q and Lin R. Hypoxia activates heparanase expression in an NF-kappaB dependent manner. Oncol Rep 2010; 23: 255-261.